To REMS, or not to REMS. That apparently was the question for Cytokinetics, which has seen any potential approval for its ...

Pliant will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech announced after ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

The National Institutes of Health (NIH) is making a major change to how grant recipients can use their funds. | The National ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

The National Institutes of Health (NIH) is planning to freeze the flow of funds to institutions outside of the U.S., ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. | With the walls quickly closing in, Kronos Bio has accepted a buyout from ...